The GENESIS Pregnancy Registry is a United States registry for pregnant women diagnosed with migraine whom may or may not have taken Aimovig® (erenumab-aooe) shortly before or during pregnancy.
By sharing your pregnancy information with this registry, you could help doctors better understand if Aimovig use before and during pregnancy affects pregnancy or newborns’ health. The possible effects will be compared with outcomes for women who have not taken Aimovig or any medication targeting the calcitonin gene-related peptide (CGRP) pathway, including Ajovy® (fremanezumab-vfrm) and Emgality® (galcanezumab-gnlm), shortly before or during their pregnancy, but who have been diagnosed with migraine. This study will follow participants throughout their pregnancy and collect health information about participants’ babies for 1 year.
You can support pregnant women in the future by joining the GENESIS Pregnancy Registry.
You may be able to participate if you have been diagnosed with migraine, are currently pregnant, and:
You will need to give written or electronic informed consent to participate in this pregnancy registry. A registry representative will speak with you over the phone to discuss the registry and what it involves. You can ask the representative any questions you may have before deciding if you want to join.
If you decide to take part and give your written or electronic informed consent, a registry representative will then:
You can download a copy of the GENESIS Pregnancy Registry Patient Brochure if you would like to discuss the registry with others, like a family member or your doctor.
With your permission, a registry representative will contact the healthcare provider caring for you during your pregnancy or the healthcare provider who is treating your migraine, and your baby’s healthcare provider. They will collect information about your general health during pregnancy and your baby’s health. Following your enrollment, a registry representative will:
The contact you and your healthcare providers will receive is summarized in the diagram below.
If you participate in the registry, you will not need to:
After you enroll in the registry, we will send you a welcome message by email. With your consent, we will also send you occasional emails and text messages to remind you about upcoming telephone interviews. You can choose to stop receiving these communications at any time. This will not affect your participation in the study.
Our FAQs contain answers to many frequently asked questions.
By clicking through the website, we understand this means you have accepted our cookies.